Aeterna Zentaris Inc. (AEZS.TO)

$6.36

+0.02 (+0.32%)
Rating:
Recommendation:
-
Symbol AEZS.TO
Price $6.36
Beta 1.709
Volume Avg. 0.00M
Market Cap 30.883M
Shares () -
52 Week Range 5.5-31.0
1y Target Est -
DCF Unlevered AEZS.TO DCF ->
DCF Levered AEZS.TO LDCF ->
ROE -21.31% Sell
ROA -16.35% Sell
Operating Margin -
Debt / Equity 32.29% Neutral
P/E -
P/B 0.57 Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades


Dr. Klaus Paulini Ph.D.
Healthcare
Biotechnology
Toronto Stock Exchange

Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is macimorelin, an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as oncology indications. The company markets macimorelin under the Macrilen brand name. Aeterna Zentaris Inc. has a license agreement with University Wuerzburg to research, develop, manufacture, and sell a potential COVID-19 vaccine; development, manufacture, and commercialization of the treatment for neuromyelitis optica spectrum disorder; and to develop human 3D intestinal tissue models to study infection biology; and for pre-clinical development towards the potential treatment of Parkinson's disease. It also has a license agreement with Consilient Health Ltd., Novo Nordisk Novo Nordisk Health Care AG, and NK MEDITECH Ltd. for the development and commercialization of macimorelin in the United States and Canada, as well as The University of Sheffield, the United Kingdom for the research, development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of primary hypoparathyroidism. Aeterna Zentaris Inc. was incorporated in 1990 and is headquartered in Summerville, South Carolina.